MET and lung carcinoma: explored the combination of rapamycin, a selective mTOR inhibitor with an E1B55KD-deleted, replication-selective oncolytic adenovirus (Ad.What), which is driven by the c-Met promoter, targeting lung cancer cells with c-Met overexpression.